# A Study to Assess the Correct Dose, Safety and Efficacy of Empasiprubart in Adolescent Participants Aged 12 to Less Than 18 Years With Chronic Inflammatory Demyelinating Polyradiculoneuropathy

> **NCT07638566** · PHASE2,PHASE3 · NOT_YET_RECRUITING · sponsor: **argenx** · enrollment: 6 (estimated)

## Conditions studied

- Chronic Inflammatory Demyelinating Polyradiculoneuropathy
- CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy)
- CIDP
- Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

## Interventions

- **BIOLOGICAL:** Empasiprubart IV

## Key facts

- **NCT ID:** NCT07638566
- **Lead sponsor:** argenx
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-09
- **Primary completion:** 2028-04
- **Final completion:** 2031-08
- **Target enrollment:** 6 (ESTIMATED)
- **Last updated:** 2026-06-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07638566

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07638566, "A Study to Assess the Correct Dose, Safety and Efficacy of Empasiprubart in Adolescent Participants Aged 12 to Less Than 18 Years With Chronic Inflammatory Demyelinating Polyradiculoneuropathy". Retrieved via MORVS 2026-10-22 from https://api.morvs.ai/clinical/NCT07638566. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*